Drug major Lupin Ltd announced plans to establish a new manufacturing facility in Coral Springs, Florida, with a projected cumulative investment of $250 million over five years. The investment will cover research and development, infrastructure, and capital expenditures, the Mumbai-based company said in a regulatory filing.
The upcoming facility will have the capacity to produce over 25 critical respiratory medicines, including albuterol inhalers for children with asthma, Lupin stated.
By strengthening domestic manufacturing and diversifying its supply chain, Lupin aims to reinforce medicine security and cement its leadership in the global respiratory segment. The company added that the project would also create over 200 new long-term skilled jobs in Broward County by 2030.
“The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy,” said Christoph Funke, Chief Technical Operations Officer, Lupin.
He added that the new site will build upon Lupin’s existing presence in Florida, which already houses its headquarters and Advanced Inhalation Research Centre.
According to the company, the Coral Springs facility will serve as the anchor for U.S. production of essential respiratory therapies, ensuring affordable and reliable access from routine pediatric care to pandemic-scale demand. The site will span 70,000 square feet on more than 5 acres of acquired land.
In recognition of its investment and job creation efforts, Lupin will receive tax credits and incentives from the state of Florida. The company is collaborating with Florida Commerce/Select Florida, the City of Coral Springs, the Greater Fort Lauderdale Alliance, the Broward County Commission, and a workforce/college partner as part of this strategic initiative.
Also Read
